Demis Hassabis, a Nobel laureate for his AI research and the CEO of Google DeepMind, said on Sunday that he hopes that AI ...

A scientific revolution is underway as researchers push to bring atomic-level precision, once reserved for small molecule ...

GenAI offers a realistic path forward in tackling previously undruggable targets, with the potential to reshape the entire ...

Its deal with the US-based AI-driven drug design and development company will see Cloud design novel small-molecule agents to GSK-specified targets. Ed Addison, CEO of Cloud Pharmaceuticals ...

Google DeepMind CEO Demis Hassabis envisions AI eradicating all diseases within a decade, potentially revolutionizing drug ...

AI, and cloud computing towards improving existing computational methods while exploring new algorithms to address a wide range of drug design challenges. “We look forward to helping expedite ...

Exscientia, headquartered in Oxford, UK, has been a pioneer in integrating AI into small-molecule drug design. The company’s platform, Centaur Chemist, combines human expertise with AI to generate ...

Historically, the vast majority of pharmaceutical drugs have been meticulously designed down to the atomic level. The ...

Forbes contributors publish independent expert analyses and insights. Gil Press writes about technology, entrepreneurs and innovation.